跳至主要内容
临床试验/SLCTR/2017/026
SLCTR/2017/026已完成4 期

Open label randomized controlled clinical trial to study the effects of achieving lowered uric acid targets with Allopurinol on rate of progression, cardiovascular morbidity and inflammatory markers of Chronic Kidney Disease of uncertain etiology (CKD-u) Sri Lanka

ational Research Council, Sri Lanka0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Males and females, aged 21 to 65 years
  • 2. eGFR equal or less than 60ml/min/1.73m2 and more than 15 ml/min/1.73m2
  • 3. Probable and confirmed CKDu according to Ministry of Health, Sri Lanka, guidelines
  • 4. Not on renal replacement therapy
  • 5. Not on urate lowering therapy other than Allopurinol
  • 6. Laboratory results of serum uric acid within the study cut off (>6mg/dl for males , >5 mg/dl for females)

排除标准

  • 1. Consumption of more than 14 drinks of alcohol per week (eg, 1 drink = 5 oz [150 mL] of wine, 12 oz [30 mL] of beer, or 1.5 oz [45 mL] of hard liquor)
  • 2. History or suspicion of drug abuse.
  • 3. History of autoimmune disease requiring systemic treatment.
  • 4. Known or suspected human immunodeficiency virus (HIV), hepatitis C antibody (HCV), or hepatitis B antibody (HBsAg) infection.
  • 5. History of malignancy within the previous 5 years (with the exception of nonmelanoma/skin cancer that has been treated with no evidence of recurrence, treated cervical dysplasia or treated in situ Grade 1 cervical cancer).
  • 6. Myocardial infarction, unstable angina, New York Heart Association (NYHA) class III or IV heart failure, or stroke within the last 12 months.
  • 7. Uncontrolled hypertension (systolic pressure above 160 mm Hg or diastolic pressure above 95 mm Hg)
  • 8. Active peptic ulcer disease requiring treatment.
  • 9. History of xanthinuria, active liver disease, or hepatic dysfunction.
  • 10. If unable to take gout flare prophylaxis of either colchicine or nonsteroidal anti-inflammatory drugs (NSAIDs) due to contraindication (e.g. toxicity, renal function, use of contraindicated medications).
  • 11. Known hypersensitivity or allergy to allopurinol

研究者

发起方
ational Research Council, Sri Lanka

相似试验